Table 4. Comparison of incidence rate of patients with glioma among countries.
Study | Country | Data source | Design | Codes of diagnostic criteria | Year | No. of new patients | Incidence rate (per 100,000) |
---|---|---|---|---|---|---|---|
Larjavaara et al.13 | Finland | 5 hospitals | Representative population-based sample | ICD-10 (C71.0–71.9) | 2000–2002 | 331 | 4.67a |
Gliomas | |||||||
Wohrer et al.12 | Austria | ABTR | Population-based registry | ICD-O-3 | 2005 | 619 | 6.89a |
Glial tumor | |||||||
Arora et al.8 | England | National Cancer Registry | Population-based regional registry | ICD-O | 1995–2003 | 27,663 | 4.88a |
Glial tumorc | |||||||
Gousias et al.14 | Greece | 7 hospitals | Prospective study | Glioma | 2005–2007 | 56 | 5.6 |
Crocetti et al.9 | Europe | RARECARE | Population-based registry | ICD-O-3 (C71.0–72) | 1995–2002 | 43,037 | 5.4b |
Glial tumor of CNS and pineal gland | |||||||
Narita et al.15 | Japan | BTRJ | Hospital-based registry | Glioma | 2001–2004 | 3,319 | 6.6 |
Rasmussen et al.16 | Denmark | DNOR | Population-based registry | Glioma | 2009–2014 | 1,930 | 7.3 |
Dhow et al.5 | South Korea | KCCR | Nationwide hospital-based cancer registry | ICD-O-3 (C71.0–71.9) | 2013 | 1,506 | 2.48a |
Glial tumorc | |||||||
Ostrom et al.10 | USA | CBTRUS | Population-based registry | ICD-O-3 | 2012–2016 | 110,324 | 6.22a |
Glial tumorc | |||||||
Walker et al.11 | Canada | Canadian Cancer Registry | Population-based registry | ICD-O-3 | 2009–2013 | 9,495 | 6.61a |
Glial tumorc | |||||||
Present study | South Korea | NHID | Population-based data | ICD-10 (C71) | 2007–2017 | 45,066 | 7.4a |
ASR = age-standardized rate, CR = crude rate, ABTR = Austrian Brain Tumor Registry, RARECARE = Surveillance of Rare Cancers in Europe, BTRJ = Brain Tumor Registry of Japan, DNOR = Danish Neuro-Oncology Registry, KCCR = Korean Central Cancer Registry, CBTRUS = Central Brain Tumor Registry of the US, NHID = National Health Insurance Database, ICD = International Classification of Disease.
aASR; bCR; cGlial tumor: astrocytic tumors, oligodendroglial tumors, mixed gliomas, ependymal tumors, glial tumors of uncertain origin, and neuronal and mixed neuronal-glial tumors.